Gut hormones have important roles in the regulation of appetite and glucose homeostasis. Understanding how macronutrient sensing in the gastrointestinal tract modulates gut hormone release may reveal novel pharmacological or dietary approaches to metabolic disease. In this short review we discuss the mechanisms by which the gut senses macronutrients and the products of macronutrient digestion, and their putative utility in treating obesity and related conditions. 
Introduction
Obesity is associated to comorbidities including cancer and diabetes [1] . The most effective therapy is gastric bypass but it is expensive and invasive. Some of the benefits of gastric bypass are attributed to changes in patients' gut hormone profiles [2] . Gut hormones, secreted by enteroendocine cells (EECs), are crucial in appetite regulation. They respond to a variety of stimuli, such as nutrients in the lumen, which are detected by a wide range of sensors [3 ] . These sensors may be useful anti-obesity targets capable of modulating endogenous gut hormone secretion to promote weight loss. This review will focus on extracellular nutrient sensors expressed in the gut, their role in gut hormone secretion and their potential use as anti-obesity targets ( Figure 1 ).
Macronutrients are classified as carbohydrates, fats or proteins. Upon ingestion, these macronutrients are converted by endogenous and bacterial enzymes to metabolites that are detected by sensors in the gut.
Carbohydrate
Glucose, a common carbohydrate and break-down product of larger carbohydrates, potently stimulates the release of the incretin and appetite-regulating hormones gastric-inhibitory peptide (GIP) and glucagon-like peptide 1 (GLP-1) when administered orally but not intravenously [4 ,5,6] . In the small intestine, this effect is primarily mediated by the sodium-dependent glucose cotransporter SGLT-1, which is expressed in both K-cells and L-cells; GIP and GLP-1 expressing EECs, respectively [5] . The entry of sodium, coupled to glucose, depolarizes the cell membrane, opening voltage gated calcium channels and stimulating hormone exocytosis [4 ,7 ] . Knockout of SGLT-1 in mice abolishes peak glucose-induced GIP and GLP-1 secretion [8, 9] , but at later time points, circulating levels of GLP-1 and the anorectic gut hormone peptide YY (PYY) are increased in both SGLT-1 À/À and antagonist treated mice [9] , suggesting alternative glucose sensing mechanisms in the distal gut. Specifically inhibiting intestinal SGLT-1 in mice also resulted in a trend for increased GLP-1 following a glucose challenge, but importantly highlighted potential gastrointestinal side effects consistent with the malabsorption observed in knockout mice and humans with SGLT-1 inactivating mutations [8, 10] .
In humans, SGLT-1 inhibition resulted in decreased postprandial GIP and increased postprandial GLP-1 levels [11] . Longer term human studies have used antagonists such as LX4211 that also target SGLT-2. Inhibiting SGLT-1/2 in diabetic patients improved glycemic control and resulted in a trend for decreased weight and increased GLP-1 and PYY levels [12] . Decreased weight gain, regardless of increased food intake was observed in animal models [13] . As an adjunct therapy to insulin in diabetic patients, LX4211 improved glycemic control, increased post-prandial PYY levels and promoted weight loss [14] . Some FDA approved SGLT-2 inhibitors also lead to weight loss [15] . Whether the gut hormone effects resulting from SGLT-1 antagonism contribute to this needs further investigation. Overall, SGLT-1 partial antagonism, to minimise malabsorption side effects, may be a better anti-obesity strategy than SGLT-1 agonism.
Glucose transporter 2 (GLUT-2) may also mediate glucose-induced gut hormone secretion. GLUT-2 inhibition and knockout in mice reduced glucose-stimulated GLP-1 secretion by $11% and 55% respectively [4 ,16] . Intestinal specific GLUT-2 knockout did not alter basal GLP-1 levels but resulted in lower L-cell density, compensated for with an 80% increase in GLP-1 content per cell [17 ] , suggesting the long-term effects of targeting GLUT-2 may differ from the acute effects. Additionally, human mutations in GLUT-2 result in Fanconi-Bickel syndrome, suggesting it may not be a useful target in the treatment of obesity [18] .
The essential role of SGLT-1 and the contributory role of GLUT-2 in GLP-1 secretion is in agreement with mathematical spatial models and transporter knockout models, but the effect of GLUT-2 knockout on glucose-induced GIP secretion is less clear [8, 16, 19] . Overall, SGLT-1 appears more important than GLUT-2 in peak glucoseinduced gut hormone secretion.
The clinical utility of targeting the heterodimer sweet taste receptor T1R2/T1R3 may also be limited. Expression of its subunits is low in K-cells and L-cells, and studies in perfused rat intestine required toxic levels of sweeteners to stimulate GLP-1 release [20] . In humans, sweeteners which activate the receptor failed to increase gut hormone release [21] . Additionally, lactisole, a T1R2/ T1R3 antagonist, failed to suppress the secretion of incretins in response to glucose in one study [22] but not in another [23] .
ATP-sensitive potassium channels (K ATP ) on EECs have also been suggested as potential sensors due to their role in b-cell glucose sensing. In rat perfused intestine, K ATP inhibition increases GLP-1 release [4 ] . However,
Targeting nutrient sensing mechanisms to treat obesity Norton and Murphy 17 sulfonylurea treatment, which leads to K ATP channel closure, failed to affect gut hormone secretion in humans during an oral glucose tolerance test [24] . In addition, individuals with K ATP channel mutations have neonatal diabetes, but normal baseline and glucose-stimulated GLP-1 levels, questioning its importance in mediating gut hormone release [25] .
There is also evidence of fructose sensing in the gut [26] and short chain fatty acids, products of carbohydrate fermentation in the colon, [27] influencing gut hormone release and appetite.
Fat
Fatty acid products of fat digestion can act intracellularly to alter metabolic processes [28] . However, there is currently much interest in the gut-based cell surface receptor systems which detect lipids. Triglycerides from dietary fat are metabolised by pancreatic lipase into long chain fatty acids, which are detected by fatty acid receptors 1 (FFAR1) and 4 (FFAR4), and 2-monoacylglycerol, detected by G-protein coupled receptor 119 (GPR119). These receptors are expressed in EECs and are thought to modulate the release of GLP-1, PYY, GIP and cholecystokinin (CCK), which is anorectic, and perhaps ghrelin, which is orexigenic, in response to dietary fat [29] [30] [31] . They thus may also have potential as anti-obesity targets.
FFAR1
À/À mice have blunted CCK, GIP and perhaps GLP-1 responses to fat ingestion, FFAR1 is therefore important in mediating the gut hormone response to dietary fat but is not essential, and likely functions alongside other sensors [29, 32, 33] . In humans, FFAR1 is expressed more than FFAR4 and GPR119 in the small intestine [32, 34] .
Known endogenous ligands of FFAR1 signal via G aq . In vivo FFAR1 is thought to synergistically interact with G as coupled receptors such as GPR119, the bile acid receptor TGR5 and the GIP receptor to potentiate GLP-1 (but not GIP) release. This can be recapitulated in vitro using second generation FFAR1 agonists that signal via both G aq and G as [30, 35] . Second generation agonists may therefore be more effective at promoting weight loss than G aq coupled first generation agonists such as TAK-875, which failed to show any clinically significant effects on body weight in clinical trials stopped due to liver toxicity concerns [36] . Gut hormone release is likely driven by basolaterally expressed FFAR1 in EECs, thus fatty acid absorption is an important step in lipid sensing; an important consideration for the design of drugs aimed at exploiting FFAR1 [37 ] .
FFAR4 is one of the most highly expressed nutrient receptors in the large intestine [38 ] . Like FFAR1, its expression in the small intestine increases in response to a high fat diet (HFD) in DIO but not DIO- GPR119, a constitutively active receptor, is expressed in K-cells and L-cells [47, 48] . In humans, GPR119 duodenal expression is inversely correlated to BMI [34] , though intraduodenal administration of lipids increases duodenal expression [49] .
GPR119 agonists stimulate GLP-1 and GIP release. The receptor is also thought to act in synergy with FFARs to potentiate GLP-1 secretion [47, 48] . The proportion of Lcells responsive to GPR119 agonists varies along the length of the gut, suggesting GPR119 may be expressed in a specific L-cell subpopulation [50] . In accord with this, GPR119 agonists-stimulated GLP-1 release is blunted in ileal and colonic cultures, but not in proximal gut cultures, from mice lacking GPR119 specifically in L-cells. In vivo, L-cell specific knockout of GPR119 reduced the GLP-1 response to lipid gastric gavage [50] and global knockout blunted GLP-1 and GIP responses to oral triglycerides [48] .
The incretin effects of GPR119 agonism have made GPR119 a popular therapeutic target [51] . However, thus far, these agonists have failed to translate to the clinic. The agonist JNJ-38431055 increased GLP-1 and GIP secretion after a meal challenge, but the resulting glucose lowering effect was insufficient to be clinically useful, and there was no effect on appetite [52] . Another agonist, GDK263, increased PYY levels by fivefold but did not affect food intake or hunger [53] . Several other clinical candidates have also been discontinued [54] , questioning the potential of GPR119 as an anti-obesity drug target.
Protein
Protein, the most satiating macronutrient, stimulates the release of various anorectic hormones including: PYY [55, 56] , CCK [57, 58] , GLP-1 [56, [59] [60] [61] and GIP [57] , which are thought to be important in protein's satiating effect. Therefore protein metabolite nutrient sensors are potential anti-obesity targets.
Three well characterised promiscuous L-amino acid sensing receptors: G protein-coupled receptor family C group 6 member A (GPRC6A), umami taste receptor T1R1/ T1R3 and the calcium sensing receptor (CaSR); a more recently identified amino acid receptor: GPR142; and the peptide receptor GPR93 are all present in the gut and appear to sense the products of protein digestion.
GPRC6A is activated by basic amino acids which trigger GLP-1 secretion in vitro in the GLUTag L-cell line, but not in primary cultures of the mouse small intestine [62, 63] . Data from GPRC6A À/À mice suggest it is not necessary for the appetite-reducing effects of high protein diets or L-arginine, or for L-arginine-induced or L-Ornithine-induced GLP-1 secretion [64,65 ,66] . Additionally, in the majority of humans, particularly Europeans and Asians, the receptor tends to be retained intracellularly, putting into question its physiological role [67] .
GPRC6A is closely related to the CaSR, making it possible to target both receptors with one agent. The CaSR is allosterically modulated by aromatic amino acids and oligopeptides. CaSR activation has been associated with the secretion of various anorectic hormones in vitro, including CCK and GLP-1 [68, 69, 70, 71 ]. CaSR antagonism decreased GLP-1, GIP and PYY secretion from small intestinal loops [72] . However, variable effects of CaSR activation on ghrelin secretion have been reported [73] . In vivo oral administration of a CaSR agonist decreased food intake in mice [74] , but at high concentrations caused emesis in mink, highlighting a potential side effect of targeting this receptor [75] .
The CaSR undergoes agonist-driven insertional signalling, making it highly resistant to functional desensitisation [76] . This, alongside its ability to stimulate the secretion of a variety of anorectic hormones, make it an interesting anti-obesity pharmacological target. However, it is widely expressed, crucial in calcium homeostasis and has multiple roles in the gastrointestinal tract which could lead to several side effects if targeted pharmacologically. In addition, mice with a gain-of-function mutation showed no difference in food intake or body weight, but did have impaired glucose tolerance and hypocalcaemia [77] .
The umami taste receptor T1R1/T1R3 in humans is particularly sensitivity to L-glutamate, whereas the rodent receptor responds to a wider range of amino acids [78, 79] . Amino acids can stimulate CCK release via T1R1/T1R3 in rodent in vitro models [79] . In pigs, signalling components of T1Rs are up-regulated in response to HPDs [80] . Whether the human receptor is also able to mediate gut hormone secretion is unknown. Additionally, there is redundancy in the system; taste cells from T1R1 À/À or T1R3 À/À mice partially responded to L-amino acids, which may reflect the detection of L-amino acids by metabotropic glutamate receptors [81] [82] [83] , and similar redundancy is possible in the gut. GPR142 is particularly activated by the essential aromatic amino acids L-phenylalanine and L-tryptophan. The concentrations of luminal amino acids following protein digestion are within the range of receptor activation [84 ] . GPR142 À/À mice have a similar food intake and body weight to control mice but the effect of agonists on food intake and body weight remain to be explored [85 ] . There is evidence that GPR142 activation can modulate gut hormone release. In mice it is expressed in gastrin-releasing G-cells and in K-cells [31, 85 ,86] . Ltryptophan simulates GIP and insulin secretion, and improves glucose tolerance in rodents via GPR142 [85 ,87] . Additionally, oral administration of a GPR142 agonist increased plasma GLP-1 in control mice but not GPR142 À/À mice [85 ] . The importance of GPR142 in energy and glucose homeostasis thus requires further investigation.
GPR93 is expressed more than other amino acid or fatty acid nutrient sensor in the small intestine [38 ] . It is found on EECs including L-cells and G-cells [38 ,88,89] . Overexpression in STC-1 cells increases the transcription and release of CCK in response to protein hydrolysate [90] and in vivo its expression may be responsive to changes in diet [89] . However, in primary cell culture, receptor knockout does not impair peptone-induced GLP-1 secretion [70] .
Some amino acid and peptide transporters can act as nutrient sensors that stimulate gut hormone release, including peptide transporter 1 (PEPT-1) and the sodium-dependent transporter of neutral amino acids, B 0 AT1, which is enriched in L-cells [91, 92] .
PEPT-1 is a proton coupled di-peptide and tri-peptide transporter expressed on the intestinal brush border. Peptide transport through PEPT1 can lead to membrane depolarisation, opening of calcium channels and subsequent secretion of GLP-1 in vitro [70, 93] . It may also indirectly mediate the secretion of gut hormones such as CCK [94] . Expression and activity of the transporter is influenced by dietary protein content [95] and may influence food intake in response to a HPD [96] . B 0 AT1 À/À animals fed a HFD have lower abdominal white adipose tissue and weight gain, increased basal levels of GIP and GLP-1, and improved glycaemic control. This phenotype may reflect the reduced absorption of protein digest products. These animals are also slightly hyperphagic, perhaps in an attempt to meet their amino acid requirements [97] . B 0 AT1 human mutations result in Hartnup disorder, suggesting it is perhaps a less than optimal anti-obesity therapy target [98] .
Conclusion
The weight loss observed in gastric bypass patients and patients treated with incretin mimetics suggest gut hormone signalling is a viable anti-obesity target. Evidence suggests that exploiting signals from multiple gut hormones concurrently would cause greater appetite suppression, and perhaps fewer side effects [99, 100] . Targeting nutrient sensors to stimulate the endogenous production of multiple gut hormones thus seems a promising avenue. However, there are a number of challenges to overcome, including understanding where in the gut such nutrients are acting, how they or mimetics can be delivered to these regions, administration regimens that avoid desensitisation of the system, and the potential for side effects. Further work is required to better understand these nutrient sensing systems to enable their effective exploitation for the prevention or treatment of obesity. 
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